High-resolution epigenome analysis in nasal samples derived from children with respiratory viral infections reveals striking changes upon SARS-CoV-2 infection - Winkley, Konner; Koseva, Boryana; Banerjee, Dithi; Cheung, Warren; Selvarangan, Rangaraj; Pastinen, Tomi; Grundberg, Elin (medRxiv, 2021)
Background DNA methylation patterns of the human genome can be modified by environmental stimuli and provide dense information on gene regulatory circuitries. We studied genome-wide DNA methylation in nasal samples from infants (<6 months) applying whole-genome bisulfite sequencing (WGBS) to characterize epigenome response to 10 different respiratory viral infections including SARS-CoV-2.Results We identified virus-specific differentially methylated regions (vDMR) with human metapneumovirus (hMPV) and SARS-CoV-2 followed by Influenza B (Flu B) causing the weakest vs. strongest epigenome response with 496 vs. 78541 and 14361 vDMR, respectively. We found a strong replication rate of FluB (52%) and SARS-CoV-2 (42%) vDMR in independent samples indicating robust epigenome perturbation upon infection. Among the FluB and SARS-CoV-2 vDMRs, around 70% were hypomethylated and significantly enriched among epithelial cell-specific regulatory elements whereas the hypermethylated vDMRs for these viruses mapped more frequently to immune cell regulatory elements, especially those of the myeloid lineage. The hypermethylated vDMRs were also enriched among genes and genetic loci in monocyte activation pathways and monocyte count. Finally, we perform single-cell RNA-sequencing characterization of nasal mucosa in response to these two viruses to functionally analyze the epigenome perturbations. Which supports the trends we identified in methylation data and highlights and important role for monocytes.Conclusions All together, we find evidence indicating genetic predisposition to innate immune response upon a respiratory viral infection. Our genome-wide monitoring of infant viral response provides first catalogue of associated host regulatory elements. Assessing epigenetic variation in individual patients may reveal evidence for viral triggers of childhood disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a CTSA grant from National Institute of Health (NIH)/NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (# UL1TR002366). Research reported in this publication was also supported by the National Institute On Minority Health And Health Disparities of the NIH under Award Number R01MD015409. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported by grants from Children's Mercy Research Institute awarded to RS, TP and EG. E.G. holds the Roberta D. Harding & William F. Bradley, Jr. Endowed Chair in Genomic Research and T.P. holds the Dee Lyons/Missouri Endowed Chair in Pediatric Genomic Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The complete WGBS project and single-cell profiling using pooled samples was determined as non-human subjects research by the Institutional Review Board (IRB) at Children's Mercy Research Institute. Single sample single-cell profiling (SARS-CoV-2) study was approved by the IRB (STUDY00001317) at Children's Mercy Research Institute.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw and processed sequencing data generated in this study have been submitted to the NCBI Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE168254 and GSE162864. Fully processed single-cell data are available for exploration through the UCSC cell browser (lifespan-nasal-atlas.cells.ucsc.edu) https://lifespan-nasal-atlas.cells.ucsc.edu SARS-CoV-2Severe acute respiratory syndrome – Coronavirus – 2FluBInfluenza Type BFluAInfluenza Type ADMRdifferentially methylated regionvDMRviral differentially methylated regionARIacute respiratory illnessWGBSwhole genome bisulfite sequencingTFBSTranscription factor binding siteAdenoAdenovirusCoronaOc43EVD68Enterovirus D68hMPVHuman metapneumovirusPIV3Human Parainfluenza Virus Type 3RSVRespiratory syncytial virusREVRhino(entro)virusGWASGenome-wide association studyscRNAseqsingle-cell RNA-sequencing